Additional file 1: Figure S1. of A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis

Abstract

Transition in CDAI for each group of patients administered TCZ at different intervals. Transition in CDAI for the 3-week group (A), 4-week group (B) and 5-week group (C). TCZ tocilizumab, CDAI clinical disease activity index. (TIF 1404 kb